Skip to main content
. 2019 Mar 7;7(1):16. doi: 10.3390/biomedicines7010016
2-AG 2-Arachidonoylglycerol
5-HT Serotonin
A(+) alcohol’s +ve effects
A(−) alcohol’s ve effects
AA arachidonic acid
AC adenylyl cyclase
ACh Acetylcholine
AChergic ACh releasing neurons
ADH alcohol dehydrogenase
ALDH acetaldehy6de dehydrogenase
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
AUC area under curve
AUD alcohol use disorder
cAMP cyclic adenosine monophosphate
CL clearance
Cmax maximum concentration
COMT catechol-O-methyl-transferase
COX Cyclooxygenase
CYP cytochrome P450
DA Dopamine
DA dopamine}
DAG Diacylglycerol
DAGL diacylglycerol lipase
DAR1 dopamine receptor 1
DAT dopamine transporter
DOR delta OPRs
DPDEP D-Pen2, D-Pen5 enkephalin, DOR agonist
EAA excitatory amino acids
eCB Endocannabinoid
eOP endogenous opioids
ERK extracellular-signal-regulated kinase
GABA γ-aminobutyric acid
GABABR GABA B receptor
GABAergic GABA releasing neurons
GHB γ-hydroxybutyric acid
GHBD GHB dehydrogenase
GIRK G protein-coupled inwardly-rectifying potassium channels
Glu Glutamate
Gluergic glutamate releasing neurons
Gly Glycine
IP3 inositol trisphosphate
KOR kappa OPRs
LDTg laterodorsal tegmental nucleus
LPS Lipopolysaccharide
METH Methamphetamine
mGluR2/3 metabolic Glu receptors 2/3
MOR mu OPRs
NAc nucleus accumbens
nAChR nicotinic ACh receptor
NAPQI N-acetyl-p-benzoquinone imine
NE Noradrenaline
NMDA N-methyl-d-Aspartate receptors
OP Opioid
OPR opioid receptors
OPRM1 A118G variant of the MOR1
PIP2 poly inositol diphosphate
pptg pedunculopontine tegmental nucleus
SERT serotonin transporter
sOP synthetic opioids
SSA succinic semialdehyde
T elimination half-life
THC Δ9-Tetrahydrocannabinol
tmax time to Cmax
TMU 1,3,7-trimethyluric acid
U50488H KOR agonist
VGSC voltage gated sodium ion (Na+) channel
VGCC voltage gated calcium ion (Ca2+) channel
VTA ventral tegmental area
α7 and α4β2 nicotinic receptor subtypes